ReviewDiscover oncology2025
Drug treatment of breast cancer brain metastases: progress and challenges.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Exploring tyrosine kinase inhibitors for HER2-positive breast cancer: comprehensive review on a complete pharmacology-molecular mechanisms, safety profiles, and insights from preclinical and clinical studies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Review
- Next Frontier in HER2+/HR+ Breast Cancer: Leveraging Cell Cycle Control with CDK4/6 Inhibitors.Journal of personalized medicine · 2026Review
- Mechanisms, Imaging Phenotypes, and Therapeutic Advances of Neovascularization in Brain Metastases.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is one of the most prevalent malignancies among women worldwide, with brain metastasis occurring in approximately 10-16% of cases, significantly contributing to poor prognosis and reduced quality of life. The treatment of breast cancer brain metastasis requires a multidisciplinary approach, prioritizing local therapies such as surgery and radiotherapy to address central nervous system lesions. However, local treatments often struggle to effectively control the progression of brain metastases and are associated with multiple complications, necessitating adjunctive systemic and supportive therapies. Following local therapy, breast cancer brain metastasis patients may benefit from systemic treatments. Pharmacological therapies, including chemotherapy, targeted therapy, immunotherapy, and antibody-drug conjugates, have emerged as vital strategies for breast cancer brain metastasis treatment. Targeted therapies combined with stereotactic radiosurgery and surgical resection have shown improved survival rates. However, challenges remain, such as high costs, limited availability of radiotherapy equipment, and individualized treatment requirements based on lesion characteristics and systemic disease control. Further advancements in pharmacological options, particularly targeted and immune therapies, offer promising avenues for improving outcomes and survival in breast cancer brain metastasis patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.